Literature DB >> 35526663

The dynamic, motile and deformative properties of RNA nanoparticles facilitate the third milestone of drug development.

Xin Li1, Abhjeet S Bhullar2, Daniel W Binzel3, Peixuan Guo4.   

Abstract

Besides mRNA, rRNA, and tRNA, cells contain many other noncoding RNA that display critical roles in the regulation of cellular functions. Human genome sequencing revealed that the majority of non-protein-coding DNA actually codes for non-coding RNAs. The dynamic nature of RNA results in its motile and deformative behavior. These conformational transitions such as the change of base-pairing, breathing within complemented strands, and pseudoknot formation at the 2D level as well as the induced-fit and conformational capture at the 3D level are important for their biological functions including regulation, translation, and catalysis. The dynamic, motile and catalytic activity has led to a belief that RNA is the origin of life. We have recently reported that the deformative property of RNA nanoparticles enhances their penetration through the leaky blood vessel of cancers which leads to highly efficient tumor accumulation. This special deformative property also enables RNA nanoparticles to pass the glomerulus, overcoming the filtration size limit, resulting in fast renal excretion and rapid body clearance, thus low or no toxicity. The biodistribution of RNA nanoparticles can be further improved by the incorporation of ligands for cancer targeting. In addition to the favorable biodistribution profiles, RNA nanoparticles possess other properties including self-assembly, negative charge, programmability, and multivalency; making it a great material for pharmaceutical applications. The intrinsic negative charge of RNA nanoparticles decreases the toxicity of drugs by preventing nonspecific binding to the negative charged cell membrane and enhancing the solubility of hydrophobic drugs. The polyvalent property of RNA nanoparticles allows the multi-functionalization which can apply to overcome drug resistance. This review focuses on the summary of these unique properties of RNA nanoparticles, which describes the mechanism of RNA dynamic, motile and deformative properties, and elucidates and prepares to welcome the RNA therapeutics as the third milestone in pharmaceutical drug development.
Copyright © 2022 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Cancer treatment; Deformative property; Drug delivery; Drug development; RNA dynamics; RNA nanotechnology; Ribonucleic acid (RNA)

Mesh:

Substances:

Year:  2022        PMID: 35526663      PMCID: PMC9257724          DOI: 10.1016/j.addr.2022.114316

Source DB:  PubMed          Journal:  Adv Drug Deliv Rev        ISSN: 0169-409X            Impact factor:   17.873


  163 in total

Review 1.  GalNAc-siRNA Conjugates: Leading the Way for Delivery of RNAi Therapeutics.

Authors:  Aaron D Springer; Steven F Dowdy
Journal:  Nucleic Acid Ther       Date:  2018-05-24       Impact factor: 5.486

Review 2.  Advances in RNA molecular dynamics: a simulator's guide to RNA force fields.

Authors:  Sweta Vangaveti; Srivathsan V Ranganathan; Alan A Chen
Journal:  Wiley Interdiscip Rev RNA       Date:  2016-10-04       Impact factor: 9.957

Review 3.  Extracellular Vesicles: Unique Intercellular Delivery Vehicles.

Authors:  Sybren L N Maas; Xandra O Breakefield; Alissa M Weaver
Journal:  Trends Cell Biol       Date:  2016-12-13       Impact factor: 20.808

Review 4.  Topoisomerase I inhibitors: camptothecins and beyond.

Authors:  Yves Pommier
Journal:  Nat Rev Cancer       Date:  2006-10       Impact factor: 60.716

5.  Multivalent Aptamer-Functionalized Single-Strand RNA Origami as Effective, Target-Specific Anticoagulants with Corresponding Reversal Agents.

Authors:  Abhichart Krissanaprasit; Carson M Key; Kristen Froehlich; Sahil Pontula; Emily Mihalko; Daniel M Dupont; Ebbe S Andersen; Jørgen Kjems; Ashley C Brown; Thomas H LaBean
Journal:  Adv Healthc Mater       Date:  2021-04-21       Impact factor: 9.933

Review 6.  RNA in motion.

Authors:  Kathleen B Hall
Journal:  Curr Opin Chem Biol       Date:  2008-10-26       Impact factor: 8.822

7.  Therapeutic effects of a novel siRNA-based anti-VEGF (siVEGF) nanoball for the treatment of choroidal neovascularization.

Authors:  Na-Kyung Ryoo; Jihwang Lee; Hyunjoo Lee; Hye Kyoung Hong; Hyejin Kim; Jong Bum Lee; Se Joon Woo; Kyu Hyung Park; Hyuncheol Kim
Journal:  Nanoscale       Date:  2017-10-19       Impact factor: 7.790

8.  RNA nanotechnology to build a dodecahedral genome of single-stranded RNA virus.

Authors:  Hui Li; Kaiming Zhang; Daniel W Binzel; Lyudmila S Shlyakhtenko; Yuri L Lyubchenko; Wah Chiu; Peixuan Guo
Journal:  RNA Biol       Date:  2021-04-29       Impact factor: 4.652

9.  Assessment and comparison of thermal stability of phosphorothioate-DNA, DNA, RNA, 2'-F RNA, and LNA in the context of Phi29 pRNA 3WJ.

Authors:  Xijun Piao; Hongzhi Wang; Daniel W Binzel; Peixuan Guo
Journal:  RNA       Date:  2017-10-19       Impact factor: 4.942

Review 10.  Engineering precision nanoparticles for drug delivery.

Authors:  Michael J Mitchell; Margaret M Billingsley; Rebecca M Haley; Marissa E Wechsler; Nicholas A Peppas; Robert Langer
Journal:  Nat Rev Drug Discov       Date:  2020-12-04       Impact factor: 84.694

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.